Abstract 5775: Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong anti-tumor activity in wild-type and mutant ER+ breast cancer models

Maysoun Shomali(Sanofi (United States)), Monsif Bouaboula(Sanofi (United States)), Gary McCort(Sanofi (France)), Albane Courjaud(Sanofi (France)), Michel Tabart(Sanofi (France)), Joanne Lager(AVEO Oncology (United States)), Bruno Filoche-Rommé(Sanofi (France)), Dietmar Hoffman, Malvika Koundinya, Zhuyan Gou, Victoria M. Richon(Memorial Sloan Kettering Cancer Center), Laurent Schio(Sanofi (France)), Timothy Ackerson, Victor Certal(Universidade do Porto), Fabienne Thompson(Sanofi (France)), Jack Pollard(Sanofi (United States)), Laurent Debüssche(Sanofi (France)), Muchun Wang, Mikhail Levit, Rosalía Arrebola(Sanofi (France)), Carlos Garcia-Echeverria(Sanofi (France)), Michael I. Weinstein(Columbia University), Pierre-Yves Abécassis(Sanofi (France)), Laurent Besret(Sanofi (France)), Andrew Hebert, Sylvie Vincent(Takeda (United States)), Hong Chen, Karl Hsu, Chris Winter, Joonil Jung(Broad Institute), Jane Cheng(Beth Israel Deaconess Medical Center), Natalia Malkova(Pennsylvania State University), Fangxian Sun(Genomics Institute of the Novartis Research Foundation), Hui Cao(Universidade de Vigo), Jessica McManus, Frank Halley(Sanofi (France)), Patrick Cohen(Sanofi (France)), Francisco Adrián(HiFiBiO Therapeutics (United States)), Youssef El‐Ahmad(Sanofi (France))
Cancer Research
July 1, 2018
Cited by 0


Related Papers